AbbVie & UroGen Overactive Bladder Treatment Misses in Phase 2 Trial

A formulation of AbbVie’s blockbuster wrinkle treatment, acquired through its buyout of Allergan, has failed a mid-stage trial as a potential fix for overactive bladder and urinary incontinence.

The FDA in 2013 approved the use of onabotulinumtoxinA (Botox) via injection into the bladder as a treatment for overactive bladder in adults who can’t take or whose condition doesn’t respond to anticholinergic medications. In 2016, Allergan struck a deal with UroGen Pharma (NASDAQ: URGN) that gave it rights to the biotech’s reverse-thermal hydrogel, or RTGel, technology to test in combination with Botox and other toxins produced by the Clostridium family of... Read more »




Author: Sarah de Crescenzo

Source : https://xconomy.com/new-york/2020/08/27/abbvie-urogen-overactive-bladder-treatment-misses-in-phase-2-trial/


Date : 2020-08-27T21:30:58.000Z

Post a Comment

Previous Post Next Post